Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Office of Medical Policy, FDA · June 17, 2026
FDA panel presented the 2025 guidance on expanded access to investigational drugs, explaining the regulatory categories, submission routes, IRB and reporting requirements, manufacturer posting requirements, safeguards (including for children), and answered clinician questions about emergency use, charging, and international limits.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.